European Generic Markets: Regulatory Approaches Across the EU

When it comes to getting affordable medicines across Europe, the system isn’t as simple as it looks. A pill that costs €2 in Poland might still be €15 in Germany-even if it’s the exact same drug. Why? Because the European Union doesn’t have one single rulebook for generic medicines. Instead, it has four different paths for approval, each with its own delays, costs, and hidden traps. And in 2025, everything changed.

How Generic Drugs Get Approved in the EU

There are four main ways a generic drug can get approved in the EU. Each one is used by different companies depending on their size, budget, and target markets. The Centralized Procedure is the fastest way to sell a generic drug across all 27 EU countries plus Iceland, Liechtenstein, and Norway. But it’s also the most expensive. Companies must submit one application to the European Medicines Agency (EMA), and if approved, the drug is authorized everywhere. This route takes about 180 days under the new 2025 rules, down from 210. But the cost? Around €425,000 in fees alone, plus another €1.2 to €1.8 million in consulting and study costs. Only big players like Sandoz or Viatris use this for high-value generics-think drugs that could bring in over €250 million in sales across Europe.

The Mutual Recognition Procedure (MRP) is the most common. About 42% of generics use this path. A company gets approval in one country-called the Reference Member State-and then asks other countries to recognize it. Sounds simple, right? In theory, yes. In practice, no. Countries often drag their feet. A 2024 IQVIA report found that while the official clock says 90 days for consensus, the real average is 132.7 days. Teva learned this the hard way with a generic version of rosuvastatin. Even after getting approval in Germany, it took over eight months to get pricing agreed upon in the Netherlands and Belgium. That’s money lost in storage, delayed sales, and lost market share.

The Decentralized Procedure (DCP) is meant for companies that want to launch in multiple countries at once-without needing prior approval anywhere. But this is where things get messy. About 38% of generics use this route, and 37% of those face delays longer than six months. Why? Because countries like Poland, Romania, or Bulgaria interpret quality standards differently than Germany or France. A stability study that passes in Paris might get rejected in Bucharest over a tiny difference in how they test polymorphic forms. A 2024 GMDP Academy case study called it a “patchwork of rules,” and generic manufacturers are fed up.

Then there’s the National Procedure. Only 5% of applications use this, and it’s usually for companies targeting one specific market. Maybe it’s France, where reimbursement rates are high. Or Austria, where there’s less competition. But this path is slow-180 to 240 days-and defeats the whole point of EU harmonization. Accord Healthcare found that getting approval in France alone took 197 days, while using MRP for the same drug across five countries took just 142 days.

The 2025 Pharma Package: What Changed

The biggest shift happened on June 4, 2025, when the EU’s Pharma Package became law. It’s the most significant update to generic drug rules in 20 years. One major change? The Bolar exemption got longer. Before, generic companies could start negotiating prices and reimbursement with health authorities only two months before a patent expired. Now, they can start six months before. That might not sound like much, but it cuts the time to market by an average of 4.3 months per product, according to REMAP Consulting’s 2025 model. That’s huge. It means generics can get on shelves faster, and payers can start comparing prices earlier-pushing down launch prices by 12-18%.

Another big change? Regulatory Data Protection. Previously, a brand-name drug’s data was protected for 10 years. Now it’s 8 years, plus one extra year if the company meets public health goals-so up to 9 years total. For some complex drugs, like biosimilars, that extra year can be extended to two. This still gives innovators enough incentive to develop new drugs, but it opens the door for generics sooner than before. Evaluate Pharma estimates this alone will speed up generic entry for 78 high-value biologics currently in development.

But not all changes are welcome. A new rule called the Transferable Exclusivity Voucher gives a 1-year bonus to companies that develop generics for rare diseases. Sounds good? Maybe. But there’s a catch: only companies with EU-wide sales over €490 million qualify. That means small and mid-sized generic firms are locked out. Big players like Sandoz can buy these vouchers and extend exclusivity on their own products. It’s a loophole that favors giants.

Why Some Countries Are Slower Than Others

It’s not just about the approval process-it’s about what happens after approval. Germany’s BfArM requires extra pharmacodynamic studies for inhalers and injectables, even when the EMA says they’re not needed. France demands specific pediatric formulations even for adult-only generics. Italy has its own impurity profiling rules for older reference products. These aren’t just paperwork-they’re delays. A 2025 ABPI survey of 47 generic companies found that 68% listed inconsistent national requirements as their biggest headache.

And then there’s the obligation to supply rule. Starting in 2025, manufacturers must ensure “sufficient quantities” of generics are available. Sounds fair. But what does “sufficient” mean? Germany says it’s 120% of demand. Romania says it’s 80%. The lack of clarity means some countries are quietly limiting supply-not because they can’t make enough, but because they don’t want to flood the market and hurt prices. Professor Panos Kanavos from LSE Health called this a “hidden barrier,” warning it could delay access in smaller markets.

Who’s Winning and Who’s Losing

Indian manufacturers now account for 38% of all generic approvals in the EU-up from 29% in 2020. Companies like Dr. Reddy’s and Sun Pharma are thriving because they focus on high-volume, low-cost generics and use the MRP and DCP to spread risk across markets. Meanwhile, European firms like Sandoz and Viatris are doubling down on the Centralized Procedure. Sandoz’s 2025 launch of a generic version of Cosentyx was a textbook success: simultaneous approval across 30 countries, 11 months faster than MRP would have allowed.

But smaller European generics? They’re stuck. The cost of Centralized Procedure is out of reach. The MRP is too unpredictable. And the DCP? Too risky. Many are turning to national approvals just to stay alive. But that’s a short-term fix. With the new ePI (electronic product information) rule coming in 2026-requiring XML submissions and €180,000-250,000 in IT upgrades-many small firms won’t survive.

What’s Next for Generic Drugs in Europe

The EU is trying to fix a broken system. The goal is to get generics to market faster, reduce shortages, and cut prices. By 2028, analysts predict generic prescriptions will rise from 65% to nearly 69.2% of all prescriptions. That’s good for patients. But the system is still fragmented. The 2025 reforms help, but they don’t fix everything. The real test will be how well national authorities align with EMA standards. If Germany, France, and Poland keep doing their own thing, patients will keep paying more and waiting longer.

For manufacturers, the lesson is clear: don’t guess the path. Study the market. Know the costs. Understand the delays. And for small companies? Focus on one country first. Build cash flow. Then expand.

For patients? The system is getting better-but not fast enough. The same pill, same science, same manufacturer, but different prices and delays across borders. That’s not efficiency. That’s bureaucracy.